Walid Saber, MD
Interventional Cardiology · Woonsocket, RINPI 1043234958
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (38.0%), travel and lodging and speaking fees — rather than concentrated in one kind of arrangement. 36 manufacturers reported payments, led by Medtronic at 58.3% of the total. Reporting peaked in 2019 at $19,689 and has fallen 89.6% since, to $2,047 in 2025.
Across 422 payments — averaging $67.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$17K
- Bard Peripheral Vascular, Inc.$4K
- Shockwave Medical, Inc$2K
- Pfizer$1K
- Johnson & Johnson$782
- Stryker$697
- plus $4K from 30 others
What the payments were for
- Consulting fees$3,80013%
- Speaking & faculty fees$6,75024%
- Travel & lodging$7,22425%
- Food & beverage$10,90738%
- Education$120%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 97 | $16,741 |
| Bard Peripheral Vascular, Inc. | 3 | $3,973 |
| Shockwave Medical, Inc | 73 | $1,507 |
| Pfizer | 56 | $1,005 |
| Johnson & Johnson | 41 | $782 |
| Stryker | 11 | $697 |
| Abbott | 15 | $688 |
| Inari Medical, Inc. | 14 | $537 |
| E.r. Squibb & Sons, L.L.C. | 28 | $497 |
| Cardiovascular Systems Inc. | 8 | $366 |
| Angiodynamics, Inc. | 4 | $289 |
| Abiomed | 1 | $235 |
| Novartis | 12 | $211 |
| Boehringer Ingelheim | 5 | $111 |
| AstraZeneca | 7 | $106 |
| Misonix Inc | 7 | $99 |
| Penumbra, Inc. | 3 | $97 |
| Boston Scientific | 4 | $97 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 6 | $82 |
| Terumo Medical Corporation | 3 | $63 |
| Philips North America LLC | 2 | $58 |
| Amarin Pharma, Inc. | 3 | $58 |
| Smith+Nephew | 2 | $51 |
| Cook Medical LLC | 2 | $49 |
| Lantheus Medical Imaging, Inc. | 2 | $48 |
| Gilead | 2 | $44 |
| Bridgebio Pharma, Inc. | 1 | $32 |
| Regeneron Healthcare Solutions, Inc. | 2 | $27 |
| Scpharmaceuticals Inc. | 1 | $27 |
| Bayer | 1 | $23 |
| Baxter Healthcare | 1 | $21 |
| Siemens Medical Solutions USA, Inc. | 1 | $20 |
| Tactile Systems Technology Inc | 1 | $16 |
| Alnylam Pharmaceuticals Inc. | 1 | $15 |
| Amgen | 1 | $14 |
| Lifenet Health | 1 | $7 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- IN.PACT Admiral$7,224
- VenaSeal$4,880
- LUTONIX$3,947
- ClosureFast$2,424
- Abre$349
- Peripheral Orbital Atherectomy System$275
- CLOTTRIEVER BOLD CATHETER$270
- Impella$235
- FLOWTRIEVER CATHETER, S$219
- CT THROMBECTOMY SYSTEM KIT$219
- Perclose ProGlide suture mediated closure system$134
- VYNDAQEL$119
- Diamondback Peripheral$117
- Supera peripheral stent system$111
How this compares
$28,694 in reported general payments places this provider in the 75th percentile of 23 interventional cardiology providers in Rhode Island.
See all interventional cardiology providers in Rhode Island →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 496 | $326,628 |
| XareltoRivaroxaban | 126 | $85,474 |
| BrilintaTicagrelor | 106 | $53,019 |
| EntrestoSacubitril/Valsartan | 30 | $20,020 |
| JardianceEmpagliflozin | 30 | $19,958 |
| FarxigaDapagliflozin Propanediol | 14 | $18,303 |
| Repatha SureclickEvolocumab | 19 | $16,101 |
| Ranolazine ErRanolazine | 134 | $12,173 |
| Praluent PenAlirocumab | 14 | $6,896 |
| Atorvastatin Calcium | 486 | $5,324 |
| ClopidogrelClopidogrel Bisulfate | 329 | $4,188 |
| Metoprolol Tartrate | 483 | $2,871 |
| Metoprolol Succinate | 272 | $2,844 |
| Rosuvastatin Calcium | 155 | $2,627 |
| Dofetilide | 17 | $2,097 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $1,005 | $326,628496 claims |
| Johnson & JohnsonXarelto | $782 | $85,474126 claims |
| AstraZenecaBrilinta, Farxiga | $106 | $71,321120 claims |
| NovartisEntresto | $211 | $20,02030 claims |
| Boehringer IngelheimJardiance | $111 | $19,95830 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 23 interventional cardiology providers in Rhode Island.
Other interventional cardiology in Woonsocket
- Peter SoukasProvidence$798K
- Jinnette AbbottProvidence$156K
- Marwan SaadProvidence$57K
- Arnav KumarWarwick$36K
- Mohammad Hashim MustehsanWarwick$29K
- Hafiz ImranProvidence$18K
- Paul GordonProvidence$13K
- Junyang LouWarwick$10K
- Omar HyderProvidence$9K
- Anum AsifProvidence$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.